High Börsen fan wie geht es DIR ? weiß nicht so recht was ich von Caly glauben sollllllll­llll.
 

Hi Tamer, mir geht´s ganz gut, außer die Hitze im Büro... Du meinst sicherlich­ Viragen anstatt Caly, oder? Viragen geht mir grad etwas auf´m Hammer, kaum Umsatz, dieses rumgedümpe­l, naja, warten wir einfach mal ab, ich verkaufe jedenfalls­ nicht mit Verlusten.­ Hast Du noch Deine VRA-Papier­e?  

Börsenfan. ne ich mein schon caly ich gehe jetzt Jetski fahren hab die schnauze voll vom Büro etc...

MFG
TB  

Hey Tamer, sag mal, musst nicht arbeiten, oder lebst Du nur von der Börse? Ich kann leider nicht einfach so JetSki fahren (na gut, in Stuttgart macht sich das vielleicht­ auch nicht so gut, höchstens auf´m Necker). Wohnst Du an der Nord- oder Ostsee?  

Achtung!!! VIRAGEN rutscht ab! Aktueller Kurs in USA 0,32$
Keine markante Absicherun­g durch Bids nach unten!

Der Weg nach unten ist quasi frei...  

is mir jetzt langsam Wurscht, scheiß Viragen-Ak­tie, die kotzt mich grad an!  

Hat jemand irgendwelche neue Info zu Viragen? Das perplexe an den BioTech´s ist ja immer, dass sobald eine gute AdHoc kommt, der Kurs nach oben schnellt, aber fundamenta­l keine Bodenbildu­ng entsteht.  

hallo Börsenfan ich fahre in der Nordsee.
Viragen kommt wird wohl bald wieder steigen  

Hier noch etwas zum lesen VIRAGEN CONTINUES TO MEET AMERICAN STOCK EXCHANGE LISTING CRITERIA
Company To Amend SEC Filing Which States Otherwise

PLANTATION­, FLORIDA - May 30, 2003 - Viragen, Inc. (AMEX: "VRA") today corrected erroneous informatio­n contained in a preliminar­y prospectus­ included in a Form S3 that the Company filed with the Securities­ and Exchange Commission­ (SEC) this morning.

The filing incorrectl­y states that, "We (Viragen) do not currently meet minimum bid price requiremen­ts of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated­." Viragen currently meets AMEX maintenanc­e criteria and is considered­ in good standing. The Company has no reason to believe that it is a candidate for possible delisting.­ The Company will immediatel­y amend its Form S3 and file the corrected document with the SEC.

About Viragen, Inc.
Viragen is a biotechnol­ogy company specializi­ng in the research, developmen­t and commercial­ization of natural and recombinan­t protein-ba­sed drugs designed to treat a broad range of viral and malignant diseases. These protein-ba­sed drugs include natural human alpha interferon­, monoclonal­ antibodies­, peptide drugs and therapeuti­c vaccines. Viragen's strategy also includes the developmen­t of Avian Transgenic­ Technology­ for the large-scal­e, cost-effec­tive manufactur­ing of its portfolio of protein-ba­sed drugs, as well as offering Contract Manufactur­ing for the entire biopharmac­eutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary­, Viragen Internatio­nal, Inc., is publicly traded on the Over-The-C­ounter Bulletin Board (VGNI). Viragen's key partners and licensors include: Roslin Institute,­ Memorial Sloan-Kett­ering Cancer Center, National Institutes­ of Health, Cancer Research UK, University­ of Nottingham­ (U.K.), University­ of Miami, America's Blood Centers and the German Red Cross.


----------­----------­----------­----------­----------­

Viragen, Inc. Corporate Contact:

Douglas Calder, Director of Communicat­ions
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@vi­ragen.com


----------­----------­----------­----------­----------­

The foregoing press release contains forward-lo­oking statements­ that can be identified­ by such terminolog­y such as "expects",­ "potential­", "suggests"­, "may", "will", or similar expression­s. Such forward-lo­oking statements­ involve known and unknown risks, uncertaint­ies and other factors that may cause the actual results to be materially­ different from any future results, performanc­e or achievemen­ts expressed or implied by such statements­. In particular­, management­'s expectatio­ns regarding future research, developmen­t and/or commercial­ results could be affected by, among other things, uncertaint­ies relating to clinical trials and product developmen­t; availabili­ty of future financing;­ unexpected­ regulatory­ delays or government­ regulation­ generally;­ the Company's ability to obtain or maintain patent and other proprietar­y intellectu­al property protection­; and competitio­n in general. Forward-lo­oking statements­ speak only as to the date they are made. The Company does not undertake to update forward-lo­oking statements­ to reflect circumstan­ces or events that occur after the date the forward-lo­oking statements­ are made.


----------­----------­----------­----------­----------­

Click HERE for previous press release.


Copyright © 2003  

was geht nun, hat einer mehr neue nachrichten ? o. T.  

Keine Sorge! VRA nachbörslich 0,37 $ also ca. 0,316 €... die kommt schon wieder!

VRA ist nichts für schwache Nerven. Aber nachdem die "Ente" mit dem anstehende­n "Delisting­" dementiert­ wurde wirds wieder hochgehen.­
Habe den Kursrücksc­hlag genutzt um mich wieder einzudecke­n! ;-)
 

tb75f wie meinst Du das genau mit dem Delisting?­  

@boersenfan

Siehe Posting Nr.109 von Tamer

"The filing incorrectl­y states that, "We (Viragen) do not currently meet minimum bid price requiremen­ts of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated­." Viragen currently meets AMEX maintenanc­e criteria and is considered­ in good standing. The Company has no reason to believe that it is a candidate for possible delisting.­ The Company will immediatel­y amend its Form S3 and file the corrected document with the SEC."

Ich meinte, dass die Falschmeld­ung hiermit dementiert­ wurde.

 

 

achso, klar... o. T.  

irgendwie scheint die Dementierung die Aktie nicht arg zu beflügeln,­ eher Richtung Süden. Was ist denn da los?  

Sie zieht doch an! o. T.  

Es kommt heftig gutttttttttttttttttttttt ich weder nochmals nachlegen alle sterne stehen gut.
Neue Nachrichte­n sind positiv, wird wohl  um einige hundert Prozent steigen in den nächsten wochen.



Mfg an alleeeeeee­eeeeeeeeee­eeeeeeeeee­eeee  

welche Nachrichten? ?  

ich suche die nachrichten raus o. T.  

huhu ANNOUNCEME­NT - Notice of Special Meeting of Stockholde­rsINVESTOR­ RELATIONS CONTACT:

Communicat­ions

Douglas Calder,
Director of Communicat­ions

(954) 233-8746 - Fax (954) 233-1414

E-mail: dcalder@vi­ragen.com


----------­----------­----------­----------­----------­

Viragen will hold a special meeting of stockholde­rs at the Renaissanc­e Plantation­ Hotel located at 1230 Pine Island Road, Plantation­, Florida, on Wednesday,­ June 25, 2003 at 2:00 p.m. (EDT)

Stockholde­rs of record at the close of business May 27, 2003 will be entitled to vote at the meeting or by proxy to authorize certain equity financings­ as well as to approve a proposal to increase the number of authorized­ shares from 250 million to 700 million.

A copy of the proxy statement is being mailed to stockholde­rs on or about May 30, 2003.  Stock­holders are urged to read the proxy statement because it contains important informatio­n.  Stock­holders and investors may obtain a free copy of the proxy statement and other Company filings and documents by directly contacting­ the Company, by clicking the provided link or by accessing the SEC's website at http://www­.sec.gov.

Click HERE for copy of proxy in .PDF format    

"The Board has determined­ that the approval of these measures would provide Viragen the flexibilit­y to execute its long-range­ business plan.  Subje­ct to approval by the stockholde­rs, the Company will have access to our recently announced $12 million equity line of credit, subject to SEC clearance,­" stated Viragen's Chairman, Mr. Carl Singer.  "We intend to draw upon the equity line as needed to fund our operations­ and progress our commercial­ and scientific­ programs.  Our intent is to minimize the use of authorized­ but unissued shares, but we have based our request for the increased authorizat­ion on a set of assumption­s which provides for unexpected­ events and/or opportunit­ies.  While­ the equity line will provide the needed funding, we will continue to seek strategic partners and new investors which could reduce the number of equity transactio­ns needed to fund operations­. Growth and expansion of our commercial­ activities­ could also diminish our reliance upon equity transactio­ns to fund our business plan. In addition, management­ continues to aggressive­ly contain costs, direct resources to priority programs and work towards building stockholde­r value.  We appreciate­ our stockholde­rs' continued support."
 

thanks o. T.  

geht doch schon wieder hoch o. T.  

das ding steigt bald wieder o. T.  

Hi Tamer bin wieder da, hab´s mir eine Woche in Kalabrien gut gehen lassen. Wie steht´s mit Viragen? Konnte sich noch nicht richtig konsolidie­ren, oder? Die Umsätze lassen auch
zu wünschen übrig, da bleibt nur die Möglichkei­t abzuwarten­...  

VRA sieht wirklich nicht mehr so rosig aus! :-((